BTIG analyst Julian Harrison maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and lowers the price target from $32 to $29.
Nvidia’s AI Chips Eat Intel’s Lunch: Here’s How Much More You’d Have Made If You Invested $1,000 In Jensen Huang’s Company Instead Of Intel In 2023
Jensen Huang-led Nvidia has emerged as one of the top gainers of the AI revolution, with its GPUs being in high demand, beating Intel.
